OPKO Health, Inc. Proceeds from Sale of Equity Method Investments
OPKO Health, Inc. (OPK) reported Proceeds from Sale of Equity Method Investments of $115.42 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-08.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfEquityMethodInvestments · last filed 2022-11-08
- OPKO Health, Inc. proceeds from sale of equity method investments for the quarter ending 2022-09-30 was $0.00.
- OPKO Health, Inc. proceeds from sale of equity method investments for the quarter ending 2021-09-30 was $0.00.
| Period end | Proceeds from Sale of Equity Method Investments 3 month | Proceeds from Sale of Equity Method Investments 6 month | Proceeds from Sale of Equity Method Investments 9 month |
|---|---|---|---|
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $115.42M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $115.42M 10-Q · filed 2022-08-04 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |